Alzheimer's disease has been described as the "looming epidemic on the horizon." More than 5 million Americans currently suffer from this neurodegenerative disease that robs patients of their memories, and this number is projected to triple by the middle of the century.
Boise State University researcher Troy Rohn is an expert in the disease process, including the statistics, symptoms and progression that will allow for a better understanding of this insidious disease. In addition, he can describe the molecular "trouble makers," providing the framework for a discussion on research goals and treatment strategies that are currently in clinical trials.
Dr. Rohn is a professor in the Department of Biological Sciences at Boise State. His research focuses on the molecular mechanisms underlying Alzheimer's disease with the goal of identifying new potential drug targets for the treatment of this disease, and he recently formulated and licensed for use by other researchers an antibody that may help determine triggers for a number of degenerative diseases.
Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies